Doubles total addressable market in the U.S. to over three million
annual procedures

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 29, 2018--
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that
is digitizing the interface between the surgeon and the patient to
improve minimally invasive surgery, today announced that the Company has
received FDA 510(k) clearance for expanded indications of its Senhance
Surgical System.

The Company received FDA 510(k) clearance for laparoscopic inguinal
hernia and laparoscopic cholecystectomy (gallbladder removal) surgery.
There are approximately 760,000 inguinal hernia and 1.2 million
laparoscopic cholecystectomy procedures performed annually in the U.S.
With this clearance, Senhance System's total addressable annual
procedures in the U.S. has more than doubled to over three million.

“This indication expansion immediately doubles the addressable market
for Senhance in the US and validates our regulatory strategy to
successfully add to our indications for use,” said Todd M. Pope,
president and chief executive officer of TransEnterix. “These expanded
procedures are commonly performed at over 95% of hospitals in the United
States. We believe this indication expansion will significantly increase
the applicability of Senhance to more institutions, particularly those
with a busy general surgery practice.”

In the U.S., Senhance is now cleared for laparoscopic colorectal,
gynecologic, inguinal hernia and cholecystectomy surgery. This enables
Senhance to be used for some of the most common abdominal surgeries,
including procedures in general surgery and gynecology.

“We have utilized Senhance broadly across a wide range of general
surgery, upper GI surgery and colorectal procedures at our institution,”
said Professor Dr. Frank Willeke, Chief of Surgery at St. Marien
Hospital in Siegen, Germany. “We believe this procedural expansion for
the US will allow surgeons there to incorporate the Senhance, as we
have, as a highly-efficient, enabling and very promising technology that
can impact the vast majority of surgeries commonly performed by general
surgeons and their sub-specialties.”

About TransEnterix

TransEnterix is a medical device company that is digitizing the
interface between the surgeon and the patient to improve minimally
invasive surgery by addressing the clinical and economic challenges
associated with current laparoscopic and robotic options in today's
value-based healthcare environment. The Company is focused on the
commercialization of the Senhance Surgical System, which digitizes
laparoscopic minimally invasive surgery. The system allows for robotic
precision, haptic feedback, surgeon camera control via eye sensing and
improved ergonomics while offering responsible economics. The Senhance
Surgical System is available for sale in the US, the EU and select other
countries. For more information, visit www.transenterix.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, which are intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks and
uncertainties that are often difficult to predict, are beyond our
control and which may cause results to differ materially from
expectations, including whether the indication expansion will
significantly increase the applicability of Senhance to more
institutions, particularly those with a busy general surgery practice
and whether the procedural expansion for the US will allow US surgeons
to incorporate the Senhance as a highly-efficient, enabling and very
promising technology that can impact the vast majority of surgeries
commonly performed by general surgeons and their sub-specialties. We
cannot assure you that our expectations will be realized. For a
discussion of the risks and uncertainties associated with TransEnterix's
business, please review our filings with the Securities and Exchange
Commission (SEC), including our Annual Report on Form 10-K filed on
March 8, 2018 and our other filings we make with the SEC. You are
cautioned not to place undue reliance on these forward looking
statements, which are based on our expectations as of the date of this
press release and speak only as of the origination date of this press
release. We undertake no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.